11月26日 - ** 药物开发商 Moleculin Biotech MBRX.O 股价早盘下跌 22%，报 0.28 美元
** 公司称将从12月1日起实施1对25的反向股票分割
** 1对25的拆股意味着每25股现有股票将合并为1股新股
** 拆股后，已发行股票将从 5170 万股减少到约 210 万股；法定股份保持 5 亿股不变 - MBRX
** 公司股票将继续在纳斯达克交易，股票代码为 "MBRX"，但使用新的识别码 - MBRX
** 公司称，拆分后持有零碎股份的股东将获得现金补偿
** 包括本交易日的走势在内，该股今年累计下跌约 83
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.